Poster Number: TCL-955

Frontline brentuximab vedotin and CHP in patients with peripheral T-cell lymphoma with <10% CD30 expression: primary analysis results from the phase 2 SGN35-032 study

Swaminathan P. Iyer,[1] Deepa Jagadeesh,[2] Eva Domingo Domènech,[3] Fabio Benedetti,[4] Antonia Rodriguez Izquierdo,[5] Krimo Bouabdallah,[6] Umberto Vitolo,[7] Tim M. Illidge,[8] Jingmin Liu,[9] Eeman Shaikh,[9] Steven M. Horwitz[10]

[1]The University of Texas MD Anderson Cancer Center, Houston, TX, USA; [2]Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland, OH, USA; [3]Institut Català d'Oncologia – Hospital Duran i Reynals, Barcelona, Spain; [4]University of Verona, Verona, Italy; [5]Hospital 12 de Octubre, Madrid, Spain; [6]Service d'hematologie clinique et therapie cellulaire, CHU Haut-Leveque, Pessac, France; [7]Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy; [8]The Christie NHS Foundation Trust, Manchester, UK; [9]Pfizer, Bothell, WA, USA; [10]Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Conclusions

- Brentuximab vedotin (BV) combined with cyclophosphamide, doxorubicin, and prednisone (A+CHP) demonstrated clinically meaningful efficacy as a frontline therapy in patients with nonsystemic anaplastic large cell lymphoma (non-sALCL) peripheral T-cell lymphoma (PTCL) regardless of CD30 expression
  - Objective response rate (ORR) at end of treatment was comparable for the CD30 <1% (61%; 95% CI, 38.5-80.3) and CD30 1% to <10% (81%; 95% CI, 62.5-92.5) cohorts
  - Median progression-free survival (PFS) and median overall survival (OS) were similar for the CD30 <1% (10.9 months and not reached [NR], respectively) and 1% to <10% (NR and NR, respectively) cohorts
- Safety was consistent with the known safety profile of A+CHP, with no new safety signals
- This study demonstrated that the efficacy and safety of A+CHP in non-sALCL PTCL with CD30 <10% were comparable to those of a similar population from ECHELON-2 with CD30 ≥10%[1,2]
- Results show that A+CHP is effective for patients with non-sALCL PTCL regardless of CD30 expression, supporting the proposed, multifaceted mechanism of action of BV in combination with CHP


Introduction

- BV, an antibody-drug conjugate targeting CD30, has shown single-agent activity in several lymphomas regardless of CD30 expression[3,4]
- The BV combination therapy of A+CHP was approved as a frontline treatment for patients with sALCL or other CD30-positive PTCL subtypes based on results from the phase 3 ECHELON-2 study (NCT01777152)[1,4]
  - A+CHP had a 30% risk reduction in PFS (stratified hazard ratio [HR], 0.70; 95% CI, 0.53-0.91; *P*=0.0077) and an OS benefit (HR, 0.72; 95% CI, 0.53-0.99; *P*=0.0424)[1]
- While high CD30 expression is a diagnostic characteristic of sALCL, CD30 expression is more variable in other PTCL subtypes[1]
- The SGN35-032 study is evaluating whether frontline A+CHP may also demonstrate efficacy in patients with non-sALCL PTCL with <10% CD30 expression[5]
- We report primary analysis results of SGN35-032

Methods

- SGN35-032 (NCT04569032; EudraCT 2020-002336-74) is an open-label, dual-cohort, global, multicenter, phase 2 study (**Figure 1**)
- Patients with newly diagnosed non-sALCL PTCL with <10% CD30 expression (by standard immunohistochemistry by local pathology assessment) were enrolled
  - Patients were assigned to either CD30 <1% or CD30 1% to <10% cohorts
- All patients received 21-day cycles of A+CHP for up to 6 to 8 cycles
- The primary endpoint, ORR following the completion of study treatment, was assessed by blinded independent central review (BICR) per Cheson 2007[6]
- Secondary endpoints included safety and complete response (CR) rate, PFS, OS, and duration of response (DOR)
- Efficacy endpoints are reported per central CD30 assessment unless otherwise noted

Figure 1: Study design



CT, computed tomography; CTCL, cutaneous T-cell lymphoproliferative disorders and lymphomas; ECOG PS, Eastern Cooperative Oncology Group performance status; FDG, fluorodeoxyglucose; MF, mycosis fungoides; PET, positron emission tomography; PML, progressive multifocal leukoencephalopathy; PO, orally; QD, once daily; TMF, transformed mycosis fungoides.
[a]Brentuximab vedotin, cyclophosphamide, and doxorubicin were administered by intravenous infusion on day 1 of each cycle. [b]Prednisone was administered orally on days 1 to 5 of each cycle.

Results

- As of July 22, 2024, a total of 82 patients received ≥1 dose of A+CHP, including 34 in the CD30 <1% cohort and 48 in the CD30 1% to <10% cohort (per local assessment)
  - Per central CD30 assessment, 23 patients were included in the CD30 <1% cohort, and 31 were included in the CD30 1% to <10% cohort
- At data cutoff, no patients were still receiving A + CHP; median follow-up was 15.7 months
- Baseline characteristics were generally balanced between the 2 cohorts (**Table 1**)

Table 1: Demographics and baseline disease characteristics

	CD30 <1%[a] (n=34)	CD30 1% to <10%[a] (n=48)	Total (N=82)
Age, median (range), years	63.0 (24-78)	64.0 (32-80)	63.5 (24-80)
Age group, n (%)			
<65 years	19 (56)	28 (58)	47 (57)
≥65 years	15 (44)	20 (42)	35 (43)
Race, n (%)			
Asian	2 (6)	4 (8)	6 (7)
Black or African American	2 (6)	2 (4)	4 (5)
White	26 (76)	37 (77)	63 (77)
Other/unknown/not reportable	4 (12)	5 (10)	9 (11)
ECOG PS, n (%)[b]			
0	15 (44)	21 (44)	36 (44)
1	16 (47)	22 (46)	38 (46)
2	2 (6)	5 (10)	7 (9)
Missing	1 (3)	0	1 (1)
Disease diagnosis, n (%)			
PTCL-NOS	18 (53)	19 (40)	37 (45)
Nodal TFH cell lymphoma	13 (38)	26 (54)	39 (48)
Other	3 (9)	3 (6)	6 (7)
Baseline IPI score, n (%)			
0/1	6 (18)	11 (23)	17 (21)
2/3	22 (65)	33 (69)	55 (67)
4/5	5 (15)	3 (6)	8 (10)
Missing	1 (3)	1 (2)	2 (2)

IPI, International Prognostic Index; PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified; TFH, T-follicular helper.
[a]CD30 expression per local testing. [b]The last nonmissing value before or on the day of first study treatment.

- Overall, the median treatment duration was 18.0 weeks (range, 3-24 weeks)
- At end of treatment, ORR was 77%, with CR rate of 63% (**Table 2**)
  - In the CD30 <1% cohort, ORR was 61%, with CR rate of 52%
  - In the CD30 1% to <10% cohort, ORR was 81%, with CR rate of 71%
- Overall median DOR was 15.9 months but NR in either cohort

Table 2: Response by BICR by CD30 status


	CD30 <1%	CD30 1% to <10%	Total
Per local CD30[a]	**n=34**	**n=48**	**N=82**
Response at EOT, n (%)[b]			
CR	19 (56)	33 (69)	52 (63)
PR	6 (18)	5 (10)	11 (13)
SD	0	3 (6)	3 (4)
PD	4 (12)	5 (10)	9 (11)
NE[c]	5 (15)	2 (4)	7 (9)
CR rate (95% CI), %[d]	56 (37.9-72.8)	69 (53.7-81.3)	63 (52.0-73.8)
ORR (95% CI), %[d]	74 (55.6-87.1)	79 (65.0-89.5)	77 (66.2-85.4)
Per central CD30[a]	**n=23**	**n=31**	**N=82[a]**
Response at EOT, n (%)[b]			
CR	12 (52)	22 (71)	52 (63)
PR	2 (9)	3 (10)	11 (13)
SD	1 (4)	1 (3)	3 (4)
PD	5 (22)	2 (6)	9 (11)
NE[c]	3 (13)	3 (10)	7 (9)
CR rate (95% CI), %[d]	52 (30.6-73.2)	71 (52.0-85.8)	63 (52.0-73.8)
ORR (95% CI), %[d]	61 (38.5-80.3)	81 (62.5-92.5)	77 (66.2-85.4)

EOT, end of treatment; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease.
[a]Based on response either at end of treatment or the first assessment after the last dose of study treatment. [b]CR, PR, SD, and PD per Cheson 2007 per independent assessor. CR, PR, SD, PD, and NE are mutually exclusive. [c]NE includes patient with no postbaseline response assessments. [d]Two-sided 95% exact CI, computed using the Clopper-Pearson method. [a]Per central testing, 28 patients either had CD30 ≥10% or were missing CD30 results.


- Median PFS was 10.9 months in the CD30 <1% cohort, NR in the CD30 1% to <10% cohort, and 12.7 months in the overall population (**Figure 2**)
- Median OS was NR in the CD30 <1% cohort, CD30 1% to <10% cohort, and overall population (**Figure 3**)

Figure 2: PFS by central CD30 status

A. CD30 <1% cohort (n=23)




B. CD30 1% to <10% cohort (n=31)




NE, not evaluable.
[a]As estimated using Kaplan-Meier methods. [b]Calculated using the complementary log-log transformation method.

Figure 3: OS by central CD30 status

A. CD30 <1% cohort (n=23)



B. CD30 1% to <10% cohort (n=31)



NE, not evaluable.
[a]As estimated using Kaplan-Meier methods. [b]Calculated using the complementary log-log transformation method.

- Most patients (95%) had a treatment-emergent adverse event (TEAE), with 59% having a grade ≥3 TEAE (**Table 3**)
  - The most common (≥10%) overall grade ≥3 TEAEs were neutropenia (18%), febrile neutropenia (17%), and anemia (10%)
- Treatment-related deaths were reported in 2 patients: decreased appetite and general physical health deterioration
- TRAEs led to treatment discontinuation in 3 patients (4%)
  - Decreased appetite, febrile neutropenia, and pneumonitis (1 patient each)
- After last treatment, 13 patients (38%) and 14 (29%) in the CD30<1% and CD30 1% to <10% cohorts, respectively, received autologous stem cell transplant

Table 3: Summary of TEAEs

	CD30 <1%[a] (n=34)	CD30 1% to <10%[a] (n=48)	Total (N=82)
Any-grade TEAEs, n (%)	32 (94)	46 (96)	78 (95)
Grade ≥3 TEAEs, n (%)	22 (65)	26 (54)	48 (59)
Most common (≥10% of total patients)			
Neutropenia	4 (12)	11 (23)	15 (18)
Febrile neutropenia	6 (18)	8 (17)	14 (17)
Anemia	2 (6)	6 (13)	8 (10)
Treatment-related TEAEs[b]	25 (74)	40 (83)	65 (79)
Most common (≥20% of total patients)			
Peripheral sensory neuropathy	11 (32)	16 (33)	27 (33)
Diarrhea	7 (21)	13 (27)	20 (24)
Nausea	7 (21)	13 (27)	20 (24)
Neutropenia	4 (12)	12 (25)	16 (20)
Serious TEAE, n (%)	15 (44)	16 (31)	31 (38)
Treatment related	9 (26)	12 (25)	21 (26)
BV related	9 (26)	10 (21)	19 (23)
TEAEs leading to dose treatment discontinuation, n (%)	2 (6)	4 (8)	6 (7)[c]
Treatment related	1 (3)	2 (4)	3 (4)[d]
BV related	1 (3)	2 (4)	3 (4)

[a]CD30 expression per local testing. [b]Per investigator determination of relatedness to any study drug. [c]These included anemia, colitis, cutaneous T-cell lymphoma, decreased appetite, febrile neutropenia, and pneumonitis. [d]These included pneumonitis, decreased appetite, and febrile neutropenia.

Electronic Poster
Please scan this quick response (QR) code with your smartphone to view an electronic version of this poster. Copies of this poster obtained through QR codes are for personal use only and may not be reproduced without written permission from the authors. If you do not have a smartphone, access the poster via the internet at: https://scientificpubs.congressposter.com/p/qzt8ztns2449foc8

Abstract Plain Language Summary
Please scan this QR code with your smartphone to view a plain language summary of the abstract. If you do not have a smartphone, access the summary via the internet at: https://scientificpubs.congressposter.com/pls/qzt8ztns2449foc8

References: 1. Horwitz S, et al. *Ann Oncol*. 2022;33(3):288-298. **2.** Horwitz S, et al. *Lancet*. 2019;393(10168):229-240. **3.** Jagadeesh D, et al. *Oncologist*. 2022;27(10):864-873. **4.** Adcetris (brentuximab vedotin). Prescribing information. Seagen; 2025. **5.** Iyer SP, et al. *J Clin Oncol*. 2024;42(16 suppl). Abstract 7069. **6.** Cheson BD, et al. *J Clin Oncol*. 2007;25(5):579-586.

Acknowledgments: Thank you to the patients and their families for their participation in the study and to all research personnel for their support of this important trial. A genAI tool (3/28/25; Pfizer; GPT-4o) developed the first draft. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication. This study was sponsored by Seagen, Inc, which was acquired by Pfizer in December 2023. Editorial support was provided by Caitlin Cash, PhD, of Nucleus Global, and was funded by Pfizer.

Correspondence: Swaminathan P. Iyer, SPIyer@mdanderson.org

Presented at the Society of Hematologic Oncology 2025 Annual Meeting
September 3-6, 2025 | Houston, TX

Previously presented at the 2025 ASCO Annual Meeting | May 30-June 3, 2025 | Chicago, IL